Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Y-mAbs Therapeutics Inc
Common Shares Outstanding
Y-mAbs Therapeutics Inc
Common Shares Outstanding Peer Comparison
Competitive Common Shares Outstanding Analysis
Latest Figures & CAGR of Competitors
Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
|
Common Shares Outstanding
$43.9m
|
CAGR 3-Years
0%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Common Shares Outstanding
$1.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
1%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Common Shares Outstanding
$1.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-2%
|
|
Amgen Inc
NASDAQ:AMGN
|
Common Shares Outstanding
$536.4m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Common Shares Outstanding
$258.3m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Common Shares Outstanding
$110.2m
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
See Also
What is Y-mAbs Therapeutics Inc's Common Shares Outstanding?
Common Shares Outstanding
43.9m
USD
Based on the financial report for Mar 31, 2024, Y-mAbs Therapeutics Inc's Common Shares Outstanding amounts to 43.9m USD.
What is Y-mAbs Therapeutics Inc's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 5Y
5%
Over the last year, the Common Shares Outstanding growth was 0%.